Dublin, May 08, 2026 (GLOBE NEWSWIRE) — The “Pancreatic Cancer Diagnostics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F” has been added to ResearchAndMarkets.com’s offering.
The Global Pancreatic Cancer Diagnostics Market is anticipated to expand from USD 3.01 Billion in 2025 to USD 4.59 Billion by 2031, reflecting a 7.29%
Growth is primarily stimulated by the increasing worldwide prevalence of the disease, its severe mortality rates, the challenges associated with early detection, and a rising need for sophisticated tools like AI-enhanced imaging and non-invasive liquid biopsies. Highlighting the critical demand for better diagnostic solutions, the American Cancer Society projects that 67,440 people in the U.S. will be diagnosed with pancreatic cancer in 2025.
However, market growth continues to be hindered by the steep costs and restricted availability of these cutting-edge technologies in certain areas, which often postpone essential patient treatment.
Market Drivers
A major catalyst for the expansion of the diagnostics market is the increasing global rate of pancreatic cancer, which drives the need for more accessible and efficient diagnostic instruments to catch the disease early and enhance patient prognosis. The continuous rise in cases emphasizes the critical need to identify this highly fatal cancer at more manageable stages, as noted in a January 2026 report by the Lustgarten Foundation citing the American Cancer Society, which highlighted a roughly 1% annual incidence increase since the 1990s.
Simultaneously, breakthroughs in diagnostic methods, including artificial intelligence, advanced imaging, and liquid biopsies, are profoundly shaping the market by providing more accurate and less invasive staging and detection options. Collaborative efforts and funding are further accelerating this progress, exemplified by NVIDIA’s August 2025 partnership with 12 global institutions to build a comprehensive pancreatic CT dataset, and AIM ImmunoTech’s April 2026 rights offering that secured around $1.8 million for metastatic pancreatic cancer research.
Market Challenges
The expansion of the Global Pancreatic Cancer Diagnostics Market is significantly hindered by the high costs and limited availability of cutting-edge diagnostic tools. The substantial financial investment needed to purchase and upkeep sophisticated imaging systems, molecular platforms, and complex biomarker assays limits their integration, especially within budget-restricted healthcare networks and developing regions, thereby reducing testing volumes and slowing overall market progress.
Additionally, this lack of widespread access to specialized technologies directly compromises patient outcomes by delaying crucial diagnoses. The Lustgarten Foundation, referencing the American Cancer Society’s 2026 report, noted that a mere 17% of patients receive a diagnosis at a localized, highly treatable stage, underscoring a major shortfall in the application of advanced diagnostic resources as financial barriers and unequal access continue to restrict the market’s reach and growth potential.
Market Trends
The Global pancreatic cancer diagnostics market is being heavily shaped by next-generation sequencing and advanced molecular profiling, which provide a profound understanding of tumor biology to help tailor personalized treatment plans. The growing accessibility and expanding reimbursement options for these sophisticated tests are encouraging broader clinical use, as seen in January 2026 when Illumina’s FDA-approved TruSight test secured CMS reimbursement at $2,989.55, smoothing the path for Medicare patients and boosting market integration.
Concurrently, the rise of multi-cancer early detection systems represents a crucial shift toward proactive screening, allowing for the identification of pancreatic and other cancers in individuals without symptoms. Innovations like Guardant Health’s Shield blood test, which achieved a 68% sensitivity rate for pancreatic cancer in a June 2025 study and earned FDA Breakthrough Device status, are vital for expanding the diagnostic market and improving early detection for this notoriously late-diagnosed disease.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2025 – 2031 |
| Estimated Market Value (USD) in 2025 | $3.01 Billion |
| Forecasted Market Value (USD) by 2031 | $4.59 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
Report Scope
Key Market Players:
- Siemens Healthineers AG
- Myriad Genetics, Inc.
- Pfizer, Inc
- Novartis AG
- AstraZeneca plc
- Immunovia AB
- Laboratory Corporation of America Holdings
- Abbott Laboratories
- Agilent Technologies, Inc.
- Thermo Fisher Scientific Inc.
Pancreatic Cancer Diagnostics Market, By Test Type:
- CT scan
- MRI
- Ultrasound
- Others
Pancreatic Cancer Diagnostics Market, By Cancer Type:
- Exocrine
- Adenocarcinoma
- Squamous Cell Carcinoma
- Colloid Carcinoma
- Others
Pancreatic Cancer Diagnostics Market, By End User:
- Hospitals & Clinics
- Diagnostic Centers
- Others
Pancreatic Cancer Diagnostics Market, By Region:
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
For more information about this report visit https://www.researchandmarkets.com/r/ymlh37
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Pancreatic Cancer Diagnostics Market
